We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

213 hedge funds and large institutions have $2.31B invested in IVERIC bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 69 increasing their positions, 63 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more call options, than puts

Call options by funds: $186M | Put options by funds: $70.8M

107% more capital invested

Capital invested by funds: $1.11B → $2.31B (+$1.2B)

104% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 28

43% more funds holding in top 10

Funds holding in top 10: 710 (+3)

16% more funds holding

Funds holding: 184213 (+29)

10% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 63

Holders
213
Holders Change
+29
Holders Change %
+15.76%
% of All Funds
3.67%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.17%
New
57
Increased
69
Reduced
63
Closed
28
Calls
$186M
Puts
$70.8M
Net Calls
+$115M
Net Calls Change
+$96.9M
Name Holding Trade Value Shares
Change
Change in
Stake
FCM
26
Farallon Capital Management
California
$23.6M +$17.3M +1,317,000 New
SC
27
Samlyn Capital
New York
$21.5M +$15.8M +1,200,486 New
Northern Trust
28
Northern Trust
Illinois
$19.7M +$196K +14,964 +1%
MB
29
MPM BioImpact
Massachusetts
$18.8M +$13.8M +1,050,000 New
PA
30
Perceptive Advisors
New York
$18.6M -$13.8M -1,053,787 -50%
Goldman Sachs
31
Goldman Sachs
New York
$18M +$3.16M +240,487 +32%
FC
32
Finepoint Capital
Massachusetts
$17.7M
IC
33
Ikarian Capital
Texas
$17.6M +$12.2M +929,684 +1,893%
PVI
34
Pura Vida Investments
New York
$17.5M +$3.42M +260,286 +36%
EA
35
Emerald Advisers
Pennsylvania
$17.3M +$12.6M +962,907 New
Adage Capital Partners
36
Adage Capital Partners
Massachusetts
$15.2M +$8.27M +630,000 +286%
Charles Schwab
37
Charles Schwab
California
$14.8M +$6.86M +522,265 +173%
SI
38
Sofinnova Investments
California
$14.7M +$2.2M +167,618 +26%
JP Morgan Chase
39
JP Morgan Chase
New York
$14.5M -$1.49M -113,564 -12%
SB
40
Samsara BioCapital
California
$14.5M -$2.65M -202,010 -20%
Skandinaviska Enskilda Banken (SEB)
41
Skandinaviska Enskilda Banken (SEB)
Sweden
$14.3M +$9.52M +725,155 +1,004%
DCM
42
Driehaus Capital Management
Illinois
$13.5M -$4.79M -364,911 -33%
AG
43
Artal Group
Luxembourg
$13.5M +$9.84M +750,000 New
EMFAT
44
Emerald Mutual Fund Advisers Trust
Pennsylvania
$13.1M +$9.61M +732,091 New
Walleye Capital
45
Walleye Capital
New York
$11.5M +$378K +28,786 +5%
Ensign Peak Advisors
46
Ensign Peak Advisors
Utah
$11.2M +$2.44M +185,886 +42%
PAMP
47
Polar Asset Management Partners
Ontario, Canada
$10.9M +$7.98M +608,100 New
Point72 Asset Management
48
Point72 Asset Management
Connecticut
$10.9M +$7.97M +606,900 New
CS
49
Candriam SCA
Luxembourg
$10.8M -$11.3M -863,739 -59%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$10.8M -$13.5M -1,027,900 -63%

ISEE Hedge Fund Activity: Q3 2022 in Review

213 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2022, worth a combined $2.31B — up 107% from $1.11B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new ISEE positions and 28 closed out — a net gain of 29 holders — while 69 added to existing stakes and 63 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $47.6M. The largest seller was Vivo Capital, cutting an estimated $62.4M.

  • 213 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2022, up from 184 in Q2 2022.
  • Funds reported $2.31B of IVERIC bio, Inc. Common Stock stock for Q3 2022, up 107% quarter-over-quarter.
  • 57 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2022 and 28 closed out, a net change of +29 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q3 2022 was RTW Investments, an estimated $47.6M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q3 2022 was Vivo Capital, an estimated $62.4M sold.

Based on aggregated 13F filings for Q3 2022.